Blood-brain barrier disruption chemotherapy

Nancy Doolittle, Tulio P. Murillo, Edward Neuwelt

Research output: Chapter in Book/Report/Conference proceedingChapter

2 Citations (Scopus)

Abstract

The efficacy of chemotherapy for malignant brain tumors has in general been disappointing, due in part to the limited passage of many systemically administered agents from the blood to the brain. The blood-brain barrier (BBB) excludes molecules from the brain based on electric charge, lipid solubility, and molecular weight. The goal of chemotherapy administered in conjunction with blood-brain barrier disruption (BBBD) is maximizing drug delivery to the brain, while preserving neurocognitive function and minimizing systemic toxicity. Translational blood-brain barrier (BBB) pre-clinical and clinical studies at Oregon Health and Science University (OHSU) evaluate the toxicity and antitumor efficacy of chemotherapeutics, chemoprotectants, and monoclonal antibodies (mAbs) as well as novel therapeutics and imaging agents. Thiols may permit increased dose intensity of agents administered in conjunction with BBBD. A current program focus is thiol chemoprotection against the hearing and bone marrow toxicity that is caused by platinum chemotherapy. In the clinic, BBBD has shown promising results in chemosensitive brain tumors such as primary central nervous system lymphoma (PCNSL) and offers a new strategy for global delivery of chemotherapy to tumors, such as anaplastic oligodendroglioma and central nervous system metastases. Current and future clinical studies include delivery of monoclonal antibodies across the BBB.

Original languageEnglish (US)
Title of host publicationHandbook of Brain Tumor Chemotherapy
PublisherElsevier Inc.
Pages262-273
Number of pages12
ISBN (Print)9780120884100
DOIs
StatePublished - 2006

Fingerprint

Blood-Brain Barrier
Drug Therapy
Sulfhydryl Compounds
Brain Neoplasms
Brain
Central Nervous System
Monoclonal Antibodies
Oligodendroglioma
Platinum
Solubility
Hearing
Lymphoma
Molecular Weight
Bone Marrow
Neoplasm Metastasis
Lipids
Health
Pharmaceutical Preparations
Neoplasms

ASJC Scopus subject areas

  • Dentistry(all)
  • Medicine(all)

Cite this

Doolittle, N., Murillo, T. P., & Neuwelt, E. (2006). Blood-brain barrier disruption chemotherapy. In Handbook of Brain Tumor Chemotherapy (pp. 262-273). Elsevier Inc.. https://doi.org/10.1016/B978-012088410-0/50056-1

Blood-brain barrier disruption chemotherapy. / Doolittle, Nancy; Murillo, Tulio P.; Neuwelt, Edward.

Handbook of Brain Tumor Chemotherapy. Elsevier Inc., 2006. p. 262-273.

Research output: Chapter in Book/Report/Conference proceedingChapter

Doolittle, N, Murillo, TP & Neuwelt, E 2006, Blood-brain barrier disruption chemotherapy. in Handbook of Brain Tumor Chemotherapy. Elsevier Inc., pp. 262-273. https://doi.org/10.1016/B978-012088410-0/50056-1
Doolittle N, Murillo TP, Neuwelt E. Blood-brain barrier disruption chemotherapy. In Handbook of Brain Tumor Chemotherapy. Elsevier Inc. 2006. p. 262-273 https://doi.org/10.1016/B978-012088410-0/50056-1
Doolittle, Nancy ; Murillo, Tulio P. ; Neuwelt, Edward. / Blood-brain barrier disruption chemotherapy. Handbook of Brain Tumor Chemotherapy. Elsevier Inc., 2006. pp. 262-273
@inbook{9a63225f8f474cc8bacc5496eb2ee2e3,
title = "Blood-brain barrier disruption chemotherapy",
abstract = "The efficacy of chemotherapy for malignant brain tumors has in general been disappointing, due in part to the limited passage of many systemically administered agents from the blood to the brain. The blood-brain barrier (BBB) excludes molecules from the brain based on electric charge, lipid solubility, and molecular weight. The goal of chemotherapy administered in conjunction with blood-brain barrier disruption (BBBD) is maximizing drug delivery to the brain, while preserving neurocognitive function and minimizing systemic toxicity. Translational blood-brain barrier (BBB) pre-clinical and clinical studies at Oregon Health and Science University (OHSU) evaluate the toxicity and antitumor efficacy of chemotherapeutics, chemoprotectants, and monoclonal antibodies (mAbs) as well as novel therapeutics and imaging agents. Thiols may permit increased dose intensity of agents administered in conjunction with BBBD. A current program focus is thiol chemoprotection against the hearing and bone marrow toxicity that is caused by platinum chemotherapy. In the clinic, BBBD has shown promising results in chemosensitive brain tumors such as primary central nervous system lymphoma (PCNSL) and offers a new strategy for global delivery of chemotherapy to tumors, such as anaplastic oligodendroglioma and central nervous system metastases. Current and future clinical studies include delivery of monoclonal antibodies across the BBB.",
author = "Nancy Doolittle and Murillo, {Tulio P.} and Edward Neuwelt",
year = "2006",
doi = "10.1016/B978-012088410-0/50056-1",
language = "English (US)",
isbn = "9780120884100",
pages = "262--273",
booktitle = "Handbook of Brain Tumor Chemotherapy",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Blood-brain barrier disruption chemotherapy

AU - Doolittle, Nancy

AU - Murillo, Tulio P.

AU - Neuwelt, Edward

PY - 2006

Y1 - 2006

N2 - The efficacy of chemotherapy for malignant brain tumors has in general been disappointing, due in part to the limited passage of many systemically administered agents from the blood to the brain. The blood-brain barrier (BBB) excludes molecules from the brain based on electric charge, lipid solubility, and molecular weight. The goal of chemotherapy administered in conjunction with blood-brain barrier disruption (BBBD) is maximizing drug delivery to the brain, while preserving neurocognitive function and minimizing systemic toxicity. Translational blood-brain barrier (BBB) pre-clinical and clinical studies at Oregon Health and Science University (OHSU) evaluate the toxicity and antitumor efficacy of chemotherapeutics, chemoprotectants, and monoclonal antibodies (mAbs) as well as novel therapeutics and imaging agents. Thiols may permit increased dose intensity of agents administered in conjunction with BBBD. A current program focus is thiol chemoprotection against the hearing and bone marrow toxicity that is caused by platinum chemotherapy. In the clinic, BBBD has shown promising results in chemosensitive brain tumors such as primary central nervous system lymphoma (PCNSL) and offers a new strategy for global delivery of chemotherapy to tumors, such as anaplastic oligodendroglioma and central nervous system metastases. Current and future clinical studies include delivery of monoclonal antibodies across the BBB.

AB - The efficacy of chemotherapy for malignant brain tumors has in general been disappointing, due in part to the limited passage of many systemically administered agents from the blood to the brain. The blood-brain barrier (BBB) excludes molecules from the brain based on electric charge, lipid solubility, and molecular weight. The goal of chemotherapy administered in conjunction with blood-brain barrier disruption (BBBD) is maximizing drug delivery to the brain, while preserving neurocognitive function and minimizing systemic toxicity. Translational blood-brain barrier (BBB) pre-clinical and clinical studies at Oregon Health and Science University (OHSU) evaluate the toxicity and antitumor efficacy of chemotherapeutics, chemoprotectants, and monoclonal antibodies (mAbs) as well as novel therapeutics and imaging agents. Thiols may permit increased dose intensity of agents administered in conjunction with BBBD. A current program focus is thiol chemoprotection against the hearing and bone marrow toxicity that is caused by platinum chemotherapy. In the clinic, BBBD has shown promising results in chemosensitive brain tumors such as primary central nervous system lymphoma (PCNSL) and offers a new strategy for global delivery of chemotherapy to tumors, such as anaplastic oligodendroglioma and central nervous system metastases. Current and future clinical studies include delivery of monoclonal antibodies across the BBB.

UR - http://www.scopus.com/inward/record.url?scp=38749105194&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38749105194&partnerID=8YFLogxK

U2 - 10.1016/B978-012088410-0/50056-1

DO - 10.1016/B978-012088410-0/50056-1

M3 - Chapter

AN - SCOPUS:38749105194

SN - 9780120884100

SP - 262

EP - 273

BT - Handbook of Brain Tumor Chemotherapy

PB - Elsevier Inc.

ER -